Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAPER: A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With Tezepelumab

NCT07363642 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07363642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07363642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAPER: A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With Tezepelumab
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
January 28, 2026
Completion date
March 31, 2029
Enrollment
400 (estimated)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma